- Home
- THAR vs CNTB Comparison
THAR vs CNTB Comparison
Compare THAR & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- CNTB
- Stock Information
- Founded
- THAR 2017
- CNTB 2012
- Country
- THAR United States
- CNTB United States
- Employees
- THAR N/A
- CNTB N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- THAR Health Care
- CNTB Health Care
- Exchange
- THAR Nasdaq
- CNTB Nasdaq
- Market Cap
- THAR 85.9M
- CNTB 93.9M
- IPO Year
- THAR 2022
- CNTB 2021
- Fundamental
- Price
- THAR $2.54
- CNTB $2.80
- Analyst Decision
- THAR Strong Buy
- CNTB Strong Buy
- Analyst Count
- THAR 1
- CNTB 3
- Target Price
- THAR $17.00
- CNTB $8.33
- AVG Volume (30 Days)
- THAR 3.5M
- CNTB 591.8K
- Earning Date
- THAR 11-12-2025
- CNTB 11-12-2025
- Dividend Yield
- THAR N/A
- CNTB N/A
- EPS Growth
- THAR N/A
- CNTB N/A
- EPS
- THAR N/A
- CNTB N/A
- Revenue
- THAR N/A
- CNTB $762,000.00
- Revenue This Year
- THAR N/A
- CNTB N/A
- Revenue Next Year
- THAR N/A
- CNTB $453,067.90
- P/E Ratio
- THAR N/A
- CNTB N/A
- Revenue Growth
- THAR N/A
- CNTB N/A
- 52 Week Low
- THAR $0.95
- CNTB $0.51
- 52 Week High
- THAR $9.08
- CNTB $3.28
- Technical
- Relative Strength Index (RSI)
- THAR 40.23
- CNTB 68.76
- Support Level
- THAR $2.18
- CNTB $1.49
- Resistance Level
- THAR $2.55
- CNTB $3.28
- Average True Range (ATR)
- THAR 0.42
- CNTB 0.33
- MACD
- THAR -0.10
- CNTB 0.12
- Stochastic Oscillator
- THAR 10.34
- CNTB 73.01
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.